Evidence Hub

HERBAMIG in the prevention of migraine headaches: results of a study based on real-life data

INSERM 1108 Faculté De Chirurgie Dentaire, Rue Braga, 63000 CLERMONT-FD, France, Rémi Shrivastava, Séverine Dameron

ASEAN Journal of Psychiatry, 2024

302 participants

Abstract

Background: Migraine is a widespread neurological disorder, affecting approximately 12% of the global population, with significant socioeconomic and personal impacts. The underdiagnosis and undertreatment of migraines exacerbate the burden, highlighting the need for effective preventive treatments. Dietary supplements, such as Tanacetum parthenium (feverfew), Salix alba (willow bark), vitamins B2 and B12, and coenzyme Q10, have shown potential benefits in migraine prevention.

Objective: This study aimed to evaluate the efficacy and safety of HERBAMIG, a dietary supplement combining these ingredients, in preventing migraine headaches.

Methods: A 3 month observational clinical follow-up was conducted in France, involving 302 participants diagnosed with episodic migraine. Patients took one capsule of HERBAMIG daily, containing 90 mg of feverfew, 150 mg of willow bark, 40 mg of coenzyme Q10, 15 mg of riboflavin, and 0.1 mg of cyanocobalamin. Primary endpoint was the change in the number of migraine days per month. Secondary endpoints included changes in migraine intensity, duration, Headache Impact Test (HIT6), and Migraine Disability Assessment Scale (MIDAS) scores.

Results: Out of 302 enrolled patients, 256 completed the study. HERBAMIG significantly reduced the number of migraine days by 28.4% (from 8.1 ± 2.5 to 5.8 ± 2.4 days per month, p<0.001). Migraine intensity decreased by 2.1 points on a 10-point scale (from 7.8 ± 1.4 to 5.7 ± 1.8, p<0.001), and duration reduced by 2.2…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free